Updated EU biosimilar guidance expected in next few months
This article was originally published in SRA
Executive Summary
As part of the ongoing process of building up its already well-established regulatory framework for biosimilars, the European Medicines Agency says it expects to finish updating its three "overarching" biosimilar guidelines in the second and third quarters of this year1.